Download PDF
Nervenheilkunde 2005; 24(08): 709-716
DOI: 10.1055/s-0038-1630008
Deutsche Gesellschaft für Muskelkranke e.V.
Schattauer GmbH

Differenzialdiagnose bei Myalgien

Bundeseinheitliche Konsensuspapiere der Neuromuskulären Zentren im Auftrag der Deutschen Gesellschaft für Muskelkranke e.V. (DGM)Differential diagnosis of myalgiasConsensus statement of the German Centers for Neuromuscular Disease
C. Berghoff
1   Neurologische Klinik der Universität Erlangen-Nürnberg
,
A. Bayas
2   Neurologische Klinik der Universität Würzburg
,
R. Gold
3   Institut für MS-Forschung, Bereich Humanmedizin der Universität Göttingen und Gemeinnützige Hertie-Stiftung
,
C. Sommer
2   Neurologische Klinik der Universität Würzburg
,
D. Pongratz
4   Friedrich-Baur-Institut München
,
D. Heuss
1   Neurologische Klinik der Universität Erlangen-Nürnberg
› Author Affiliations
Further Information

Publication History

Eingegangen am: 30 October 2004

angenommen am: 31 October 2004

Publication Date:
31 January 2018 (online)

    Permissions and Reprints

Zusammenfassung

Myalgien können als unspezifisches Symptom bei einer Vielzahl neurologischer und anderer Erkrankungen auftreten. Häufig sind diese Schmerzen nicht durch eine primäre Schädigung des Skelettmuskels selbst verursacht, sondern Begleitsymptome unterschiedlicher Erkrankungen. Primäre muskuläre Ursachen müssen jedoch bedacht werden, um entsprechend zu beraten und eine angemessene Therapie anbieten zu können.

In der vorliegenden Arbeit werden Myopathien und primär nicht muskuläre Erkrankungen im Hinblick auf die Differenzialdiagnose von Muskelschmerzen vorgestellt.

Summary

Myalgia is a common non specific symptom associated with a variety of neurological and other diseases. Often muscle pain is not caused by direct damage of the skeletal muscle itself, but is rather a non specific accompanying feature of different diseases. Still, disorders of the skeletal muscle must be considered to provide adequate counselling and therapy for these patients.

Here we summarise myopathies and other disorders not due to primary damage of the skeletal muscle in the context of the differential diagnosis of muscle pain.

Schlüsselwörter

Myalgie - Muskelschmerz - Differenzialdiagnose

Keywords

Myalgia - muscle pain - differential diagnosis
 

  • Literatur

  • 1 Hays AP, Gamboa ET. Acute viral myositis. In: Myology. Engel AG. (Ed). New York: McGraw Hill; 1994: 1399-418.
    Google Scholar
  • 2 Müller-Felber W. et al. Myositis in Lyme borreliosis: an immunohistochemical study of seven patients. J Neurol Sci 1993; 118: 207-12.
    CrossrefPubMedGoogle Scholar
  • 3 Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
    CrossrefPubMedGoogle Scholar
  • 4 Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
    CrossrefPubMedGoogle Scholar
  • 5 Heuss D. et al. Myopathological findings in interstitial myositis in type II polyendocrine autoimmune syndrome (Schmidt’s syndrome). Neurol Res 1995; 17: 233-7.
    CrossrefPubMedGoogle Scholar
  • 6 Angelini C. et al. Clinical varieties of carnitine and carnitine palmitoyltransferase deficiency. Clin Biochem 1987; 20: 1-7.
    CrossrefPubMedGoogle Scholar
  • 7 Fingerhut R. et al. Hepatic carnitine palmitoyltransferase I deficiency: acylcarnitine profiles in blood spots are highly specific. Clin Chem 2001; 47: 1763-8.
    PubMedGoogle Scholar
  • 8 Gempel K. et al. Screening for carnitine palmitoyltransferase II deficiency by tandem mass spectrometry. J Inherit Metab Dis 2002; 25: 17-27.
    CrossrefPubMedGoogle Scholar
  • 9 Morisaki T. et al. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci USA 1992; 89: 6457-61.
    CrossrefPubMedGoogle Scholar
  • 10 Gross M. et al. A G468-T AMPD1 mutant allele contributes to the high incidence of myoadenylate deaminase deficiency in the Caucasian population. Neuromuscul Disord 2002; 12: 558-65.
    CrossrefPubMedGoogle Scholar
  • 11 Baumeister FA. et al. Myoadenylate deaminase deficiency with severe rhabdomyolysis. Eur J Pediatr 1993; 152: 513-5.
    CrossrefPubMedGoogle Scholar
  • 12 Gold R. et al. Becker muscular dystrophy: detection of unusual disease courses by combined approach to dystrophin analysis. Muscle Nerve 1992; 15: 214-8.
    CrossrefPubMedGoogle Scholar
  • 13 Rosenfeld J, Sloan-Brown K, George AL. A novel muscle sodium channel mutation causes painful congenital myotonia. Ann Neurol 1997; 42: 811-4.
    CrossrefPubMedGoogle Scholar
  • 14 Ricker K. et al. Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology 1994; 44: 1448-52.
    CrossrefPubMedGoogle Scholar
  • 15 Schneider C, Reiners K, Toyka KV. Myotone Dystrophy (DM/Curschmann-Steinert-Erkrankung) und proximale myotone Myopathie (PROMM/Ricker-Syndrom). Myotone Muskelerkrankungen mit multisystemischen Manifestationen. Nervenarzt 2001; 72: 618-24.
    CrossrefPubMedGoogle Scholar
  • 16 Day JW. et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 2003; 60: 657-64.
    CrossrefPubMedGoogle Scholar
  • 17 George A. et al. Musculosceletal pain in myotonic dystrophy type 2. Arch Neurol 2004; 61: 1938-42.
    PubMedGoogle Scholar
  • 18 Schneider C, Koch MC. Multisystemische myotone Myopathien, in Neuromuskuläre Erkrankungen. Pongratz D. (Ed), Köln: Deutscher Ärzte-Verlag; 2003: 117-39.
    Google Scholar
  • 19 Vihola A. et al. Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/ DM2. Neurology 2003; 60: 1854-7.
    CrossrefPubMedGoogle Scholar
  • 20 Lochmüller H. et al. Exercise-induced myalgia in hypothyroidism. Clin Investig 1993; 71: 999-1001.
    PubMedGoogle Scholar
  • 21 Wolfe F. et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160-72.
    CrossrefPubMedGoogle Scholar
  • 22 Le Quintrec JS, Le Quintrec JL. Drug induced myopathies. Bailliere’s Clinical Rheumatology 1991; 5: 21-38.
    PubMedGoogle Scholar
  • 23 Stoltenburg-Didinger G, Neuhaus GA. Toxische Ursachen von Muskelschmerzen. Internist (Berl) 1987; 28: 596-605.
    PubMedGoogle Scholar
  • 24 Sieb JP, Gillessen T. Iatrogenic and toxic myopathies. Muscle Nerve 2003; 27: 142-56.
    CrossrefPubMedGoogle Scholar
  • 25 Hengstman GJ. et al. Myositis during long-term interferon-alpha treatment. Neurology 2000; 54: 2186.
    CrossrefPubMedGoogle Scholar
  • 26 Döser S. et al. Empfehlung zur Statintherapie im Alter. Internist (Berl) 2004; 45: 1053-62.
    PubMedGoogle Scholar
  • 27 Pasternak RC. et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke 2002; 33: 2337-41.
    CrossrefPubMedGoogle Scholar
  • 28 Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. Jama 2003; 289: 1681-90.
    CrossrefPubMedGoogle Scholar
  • 29 Kaufman LD, Krupp LB. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol 1995; 7: 560-7.
    CrossrefPubMedGoogle Scholar
  • 30 Sullivan EA. et al. The natural history of eosinophilia-myalgia syndrome in a tryptophan-exposed cohort in South Carolina. Arch Intern Med 1996; 156: 973-9.
    CrossrefPubMedGoogle Scholar
  • 31 Meinck HM. Das Stiff-man-Syndrom aus neurologischer Sicht. Internist (Berl) 2000; 41: 455-9.
    CrossrefPubMedGoogle Scholar
  • 32 Wessig C. et al. Neuropathology and binding studies in anti-amphiphysin-associated stiff-person syndrome. Neurology 2003; 61: 195-8.
    CrossrefPubMedGoogle Scholar
  • 33 Vincent A. Understanding neuromyotonia. Muscle Nerve 2000; 23: 655-7.
    CrossrefPubMedGoogle Scholar
  • 34 Zierz S, Jerusalem F. Neuromyotonie, in Muskelerkrankungen. Stuttgart: Georg Thieme Verlag; 2003: 186-7.
    Google Scholar
  • 35 Karpati G. et al. Myopathy caused by a deficiency of Ca2+-adenosine triphosphatase in sarcoplasmic reticulum (Brody’s disease). Ann Neurol 1986; 20: 38-49.
    CrossrefPubMedGoogle Scholar
  • 36 Odermatt A. et al. Mutations in the gene-encoding SERCA1, the fast-twitch skeletal muscle sarcoplasmic reticulum Ca2+ ATPase, are associated with Brody disease. Nat Genet 1996; 14: 191-4.
    CrossrefPubMedGoogle Scholar
  • 37 Taylor DJ. et al. Ca2+-ATPase deficiency in a patient with an exertional muscle pain syndrome. J Neurol Neurosurg Psychiatry 1988; 51: 1425-33.
    CrossrefPubMedGoogle Scholar
  • 38 Ricker K, Moxley RT, Rohkamm R. Rippling muscle disease. Arch Neurol 1989; 46: 405-8.
    CrossrefPubMedGoogle Scholar
  • 39 Alberca R. et al. Increased mechanical muscle irritability syndrome. Acta Neurol Scand 1980; 62: 250-4.
    PubMedGoogle Scholar
  • 40 Roke ME. et al. Myopathy in primary systemic amyloidosis. Can J Neurol Sci, 1988; 15: 314-6.
    CrossrefPubMedGoogle Scholar
  • 41 Zierz S, Jerusalem F. Amyloidmyopathie, in Muskelerkrankungen. Stuttgart: Georg Thieme Verlag; 2003: 339.
    Google Scholar
  • 42 Troost D. et al. Immunohistological alterations in muscle of patients with amyotrophic lateral sclerosis: mononuclear cell phenotypes and expression of MHC products. Clin Neuropathol 1992; 11: 115-20.
    PubMedGoogle Scholar
  • 43 Dalakas M. Postpolio syndrome. Curr Opin Rheumatol 1990; 2: 901-7.
    CrossrefPubMedGoogle Scholar
  • 44 Jubelt B, Agre JC. Characteristics and management of postpolio syndrome. Jama 2000; 284: 412-4.
    CrossrefPubMedGoogle Scholar
  • 45 Ropper AH, Shahani BT. Pain in Guillain-Barre syndrome. Arch Neurol 1984; 41: 511-4.
    CrossrefPubMedGoogle Scholar
  • 46 Pentland B, Donald SM. Pain in the Guillain-Barre syndrome: a clinical review. Pain 1994; 59: 159-64.
    CrossrefPubMedGoogle Scholar
  • 47 Pearn J. Neurology of ciguatera. J Neurol Neurosurg Psychiatry 2001; 70: 4-8.
    CrossrefPubMedGoogle Scholar
  • 48 Ruprecht K, Rieckmann P, Giess R. Ciguatera: Klinische Bedeutung eines marinen Neurotoxins. Dtsch Med Wochenschr 2001; 126: 812-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Blume C. et al. Die CiguateraVergiftung – wachsende differentialdiagnostische Bedeutung im Zeitalter des Fernreisetourismus. Med Klin (Munich) 1999; 94: 45-9.
    PubMedGoogle Scholar
  • 50 Arendt G, Grabensee B. Ciguatera: Klinische Bedeutung eines marinen Neurotoxins. Dtsch Med Wochenschr 2001; 126: 1381-2.
    Article in Thieme ConnectPubMedGoogle Scholar